How to Switch Patients to Biosimilars

Roy M. Fleischmann, MD: The other point you raised is that if a patient doesn’t respond to brand name adalimumab, would you expect them to respond to the biosimilar? I agree with you. Why should they? They don’t have it. The likelihood of them not doing so is probably 98%. Why take that 2% chance? … Read more